Physician profile
Lisa Chadwick
NPI 1790765782
$13,996.23
in general payments reported to CMS, 2019-2025
41 companies · $54.54 in 2025
The $54.54 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,516 · 2020: $2,435 · 2021: $2,855 · 2022: $3,190 · 2023: $3,085 · 2024: $861 · 2025: $54.54.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,980 · Education: $20.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,979.96 |
| Education | $20.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,262.68 | 2019-2024 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $2,054.88 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Lilly USA, LLC | $1,546.97 | 2019-2024 | Mounjaro, Trulicity, Jardiance |
| Glaxosmithkline, LLC. | $1,358.80 | 2019-2024 | Trelegy Ellipta, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,150.56 | 2019-2024 | Jardiance, Stiolto Respimat, Synjardy |
| Pfizer INC. | $1,140.23 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $903.37 | 2019-2024 | Farxiga, Breztri, Fasenra |
| Janssen Pharmaceuticals, INC | $744.03 | 2019-2024 | Spravato, Xarelto |
| Amarin Pharma, INC. | $389.35 | 2019-2023 | |
| Allergan, INC. | $379.70 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $323.29 | 2021-2024 | |
| Amgen INC. | $264.71 | 2019-2024 | Evenity, Prolia, Tezspire |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $220.75 | 2021-2024 | Xifaxan, Trulance |
| Sanofi-Aventis U.S. LLC | $149.20 | 2020-2022 | |
| Radius Health, INC. | $124.72 | 2019 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Chadwick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.